<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04438512</url>
  </required_header>
  <id_info>
    <org_study_id>EA</org_study_id>
    <nct_id>NCT04438512</nct_id>
  </id_info>
  <brief_title>A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD</brief_title>
  <acronym>EAMP1</acronym>
  <official_title>An Intermediate-size Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multidisciplinary Association for Psychedelic Studies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Multidisciplinary Association for Psychedelic Studies</source>
  <brief_summary>
    <textblock>
      This is an open-label, expanded access protocol for eligible patients with&#xD;
      treatment-resistant posttraumatic stress disorder (PTSD). This protocol is designed to&#xD;
      provide access to MDMA-assisted therapy for patients who are not eligible for participation&#xD;
      in another ongoing MDMA-assisted therapy clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PTSD is a serious debilitating disorder that negatively impacts a person's daily life, and&#xD;
      can result in diminished cognitive and psychosocial functioning, fractured relationships,&#xD;
      inability to maintain employment, substance abuse, high-cost healthcare utilization,&#xD;
      increased depression, and suicide risk. People who suffer from PTSD relive their traumatic&#xD;
      experience(s) through nightmares and flashbacks, have difficulty sleeping, and feel detached&#xD;
      or estranged. Symptoms can be severe and long lasting.&#xD;
&#xD;
      3,4-methylenedioxymethamphetamine (MDMA) is a drug that releases serotonin, norepinephrine&#xD;
      and dopamine in the brain and indirectly increases levels of the neurohormones oxytocin,&#xD;
      arginine vasopressin and cortisol. The combined neurobiological effects of MDMA increase&#xD;
      compassion, reduce defenses and fear of emotional injury, and enhance communication and&#xD;
      introspection. MDMA produces anxiolytic and prosocial effects, which counteract avoidance and&#xD;
      hyperarousal in the context of therapy. A combined treatment of MDMA and therapy may be&#xD;
      especially useful for treating PTSD. The subjective effects of MDMA create a productive&#xD;
      psychological state that enhances the therapeutic process.&#xD;
&#xD;
      This is an open-label, expanded access protocol for eligible patients with&#xD;
      treatment-resistant PTSD. This protocol is designed to provide access to MDMA-assisted&#xD;
      therapy for patients who are not eligible for participation in another ongoing MDMA-assisted&#xD;
      therapy clinical trial. In addition, this study will provide supportive data on safety and&#xD;
      tolerability of MDMA-assisted therapy in treatment-resistant patients with PTSD. The study&#xD;
      will treat up to 50 patients. A flexible dose of MDMA, followed by a supplemental dose unless&#xD;
      contraindicated, is administered during the Treatment Period with manualized therapy in up to&#xD;
      three open-label Experimental Sessions. During the Treatment Period, each Experimental&#xD;
      Session is preceded by three 90-minute Preparatory Sessions and followed by three 90-minute&#xD;
      Integrative Sessions of non-drug therapy. Experimental Sessions will be followed by an&#xD;
      overnight stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Post Traumatic Stress Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>Administration of 80 or 120 mg MDMA in combination with psychotherapy and a supplemental dose offered 1.5/2 hrs later of 40 or 60 mg MDMA respectively</description>
    <other_name>3,4-methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychotherapy</intervention_name>
    <description>Standardized non-directive psychotherapy performed by therapist team</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At Screening, meet criteria for PTSD diagnosis according to medical history and&#xD;
             clinical interview and have at least moderate PTSD symptoms in the last month.&#xD;
&#xD;
          -  Have had at least two unsuccessful attempts at treatment for PTSD. Treatment attempts&#xD;
             can consist of adequate dose and duration of medication treatment (at least 3 months&#xD;
             of Paroxetine or Sertraline or other SSRI at dosages recommended in the package&#xD;
             insert) or adequate duration of therapy treatment (at least 12 sessions of&#xD;
             psychotherapy) or any combination of these two categories.&#xD;
&#xD;
          -  Are at least 18 years old.&#xD;
&#xD;
          -  Are fluent in speaking and reading a recognized language of the expanded access site.&#xD;
&#xD;
          -  Are able to swallow pills.&#xD;
&#xD;
          -  Agree to have study visits recorded, if applicable, including Experimental Sessions&#xD;
             and non-drug therapy sessions.&#xD;
&#xD;
          -  Must provide a contact (relative, spouse, close friend or other support person) who is&#xD;
             willing and able to be reached by the investigators in the event of a patient becoming&#xD;
             suicidal or unreachable.&#xD;
&#xD;
          -  Must agree to inform the investigators within 48 hours of any medical conditions and&#xD;
             procedures.&#xD;
&#xD;
          -  If a patient has the ability to become pregnant, they must have a negative pregnancy&#xD;
             test at program entry and prior to each Experimental Session, and must agree to use&#xD;
             adequate contraception through 10 days after the last Experimental Session.&#xD;
&#xD;
          -  Agree to the following lifestyle modifications: comply with requirements for fasting&#xD;
             and refraining from certain medications prior to Experimental Sessions, not&#xD;
             participate in any other interventional clinical trials during the duration of the&#xD;
             protocol without prior approval of the medical monitor, remain overnight at the site,&#xD;
             or nearby location, after each Experimental Session and be driven home on the&#xD;
             following day, and commit to medication dosing, therapy, and program procedures.&#xD;
&#xD;
          -  May have well-controlled hypertension that has been successfully treated with&#xD;
             anti-hypertensive medicines, if they pass additional screening within the past year to&#xD;
             rule out underlying cardiovascular disease.&#xD;
&#xD;
          -  May have asymptomatic Hepatitis C virus (HCV) that has previously undergone evaluation&#xD;
             and treatment as needed.&#xD;
&#xD;
          -  May have current alcohol or substance use disorder if patient meets criteria for early&#xD;
             remission prior to enrollment.&#xD;
&#xD;
          -  May have a history of or current Diabetes Mellitus (Type 1 or Type 2), if the patient&#xD;
             passes additional screening to rule out underlying cardiovascular disease&#xD;
&#xD;
          -  May have hypothyroidism if taking adequate and stable thyroid replacement medication.&#xD;
&#xD;
          -  May have a history of, or current glaucoma, if approval for program participation is&#xD;
             received from an ophthalmologist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are not able to give adequate informed consent.&#xD;
&#xD;
          -  Have any current problem which, in the opinion of the investigator or medical monitor,&#xD;
             might interfere with participation.&#xD;
&#xD;
          -  In the investigator's opinion, lack a stable living situation or supportive&#xD;
             family/network.&#xD;
&#xD;
          -  Have evidence or history of significant medical and psychiatric disorders.&#xD;
&#xD;
          -  Any patient presenting current serious suicide risk.&#xD;
&#xD;
          -  Would present a serious risk to others as established through clinical interview and&#xD;
             contact with treating psychiatrist.&#xD;
&#xD;
          -  Have evidence or history of significant hematological, endocrine, cerebrovascular,&#xD;
             cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or&#xD;
             neurological disease, including seizure disorder, or any other medical disorder judged&#xD;
             by the investigator to significantly increase the risk of MDMA.&#xD;
&#xD;
          -  Have a history of ventricular arrhythmia, other than occasional PVCs in the absence of&#xD;
             ischemic heart disease, at any time or with a history of supraventricular arrhythmia&#xD;
             within the past year.&#xD;
&#xD;
          -  Have a diagnosis of uncontrolled hypertension using the standard criteria of the&#xD;
             American Heart Association for Stage 2 hypertension (values of 140/90 milligrams of&#xD;
             Mercury [mmHg] or higher assessed on three separate occasions).&#xD;
&#xD;
          -  Have a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration&#xD;
             of a QTc interval &gt;450 milliseconds [ms] corrected by Fridericia's formula).&#xD;
&#xD;
          -  Have a history of additional risk factors for Torsade de pointes (e.g., heart failure,&#xD;
             hypokalemia, family history of Long QT Syndrome).&#xD;
&#xD;
          -  Require use of concomitant medications that prolong the QT/QTc interval during&#xD;
             Experimental Sessions.&#xD;
&#xD;
          -  Have symptomatic liver disease or have significant liver enzyme elevation.&#xD;
&#xD;
          -  Have a history of HCV that has not been evaluated and treated successfully if&#xD;
             treatment is indicated.&#xD;
&#xD;
          -  Have history of hyponatremia or hyperthermia.&#xD;
&#xD;
          -  Are pregnant or nursing, or able to become pregnant and are not practicing an&#xD;
             effective means of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Linda Iovanni</last_name>
    <role>Study Director</role>
    <affiliation>MAPS PBC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunstone Medical, PC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Psychedelic Institute</name>
      <address>
        <city>Waynesville</city>
        <state>North Carolina</state>
        <zip>28786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>August 28, 2023</last_update_submitted>
  <last_update_submitted_qc>August 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04438512
org study id: EA
nct id: NCT04438512
lead sponsor: 
This is an open-label, expanded access protocol for eligible patients with
      treatment-resistant posttraumatic stress disorder (PTSD). This protocol is designed to
      provide access to MDMA-assisted therapy for patients who are not eligible for participation
      in another ongoing MDMA-assisted therapy clinical trial.
PTSD is a serious debilitating disorder that negatively impacts a person's daily life, and
      can result in diminished cognitive and psychosocial functioning, fractured relationships,
      inability to maintain employment, substance abuse, high-cost healthcare utilization,
      increased depression, and suicide risk. People who suffer from PTSD relive their traumatic
      experience(s) through nightmares and flashbacks, have difficulty sleeping, and feel detached
      or estranged. Symptoms can be severe and long lasting.

      3,4-methylenedioxymethamphetamine (MDMA) is a drug that releases serotonin, norepinephrine
      and dopamine in the brain and indirectly increases levels of the neurohormones oxytocin,
      arginine vasopressin and cortisol. The combined neurobiological effects of MDMA increase
      compassion, reduce defenses and fear of emotional injury, and enhance communication and
      introspection. MDMA produces anxiolytic and prosocial effects, which counteract avoidance and
      hyperarousal in the context of therapy. A combined treatment of MDMA and therapy may be
      especially useful for treating PTSD. The subjective effects of MDMA create a productive
      psychological state that enhances the therapeutic process.

      This is an open-label, expanded access protocol for eligible patients with
      treatment-resistant PTSD. This protocol is designed to provide access to MDMA-assisted
      therapy for patients who are not eligible for participation in another ongoing MDMA-assisted
      therapy clinical trial. In addition, this study will provide supportive data on safety and
      tolerability of MDMA-assisted therapy in treatment-resistant patients with PTSD. The study
      will treat up to 50 patients. A flexible dose of MDMA, followed by a supplemental dose unless
      contraindicated, is administered during the Treatment Period with manualized therapy in up to
      three open-label Experimental Sessions. During the Treatment Period, each Experimental
      Session is preceded by three 90-minute Preparatory Sessions and followed by three 90-minute
      Integrative Sessions of non-drug therapy. Experimental Sessions will be followed by an
      overnight stay.
expanded access type intermediate: Yes
expanded access type treatment: Yes
intervention type: Drug
intervention name: MDMA
description: Administration of 80 or 120 mg MDMA in combination with psychotherapy and a supplemental dose offered 1.5/2 hrs later of 40 or 60 mg MDMA respectively
other name: 3,4-methylenedioxymethamphetamine
intervention type: Behavioral
intervention name: Psychotherapy
description: Standardized non-directive psychotherapy performed by therapist team
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
last name: Linda Iovanni
role: Study Director
affiliation: MAPS PBC
facility: 
facility: 
country: United States
responsible party type: Sponsor
mesh term: Stress Disorders, Traumatic
mesh term: Stress Disorders, Post-Traumatic
mesh term: N-Methyl-3,4-methylenedioxyamphetamine